Maze Therapeutics (MAZE) Stock Price, News & Analysis

Company Overview

Maze Therapeutics, Inc. (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas. By integrating large‐scale genetic datasets with functional genomics assays, the company seeks to uncover previously unrecognized pathways that can be modulated by small molecules or biologics. Its target selection strategy is designed to deliver higher confidence in clinical proof‐of‐concept studies, and Maze’s research collaborations with academic and industry partners support the advancement of its most promising candidates through preclinical and early clinical stages.

Headquartered in South San Francisco, California, Maze Therapeutics operates within a vibrant biotech cluster and draws on a network of scientific advisors and strategic collaborators worldwide. The company is led by a management team with extensive experience in genomics, drug development and translational research. By focusing on genetically validated targets and a disciplined go-to-clinic approach, Maze aims to bring transformative therapies to patients in need while creating value for its shareholders.

Key Stats

• Today's Range: $22.01 to $25.48
• 50-Day Range: $12.12 to $24.80
• 52-Week Range: $6.71 to $25.50
• Volume: 1.27 million shs
• Average Volume: 598,170 shs
• Market Capitalization: $1.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.17
• Consensus Rating: Buy

MAZE Stock Analysis - Frequently Asked Questions

How have MAZE shares performed this year?

Maze Therapeutics' stock was trading at $13.38 at the beginning of the year. Since then, MAZE shares have increased by 74.1% and is now trading at $23.30.

How were Maze Therapeutics' earnings last quarter?

Maze Therapeutics, Inc. (NASDAQ:MAZE) issued its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.02.

When did Maze Therapeutics IPO?

Maze Therapeutics (MAZE) raised $140 million in an initial public offering (IPO) on Friday, January 31st 2025. The company issued 8,750,000 shares at a price of $16.00 per share.

When did the company's lock-up period expire?

Maze Therapeutics's lock-up period expired on Wednesday, July 30th. Maze Therapeutics had issued 8,750,000 shares in its initial public offering on January 31st. The total size of the offering was $140,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.

Who are Maze Therapeutics' major shareholders?

Maze Therapeutics' top institutional shareholders include Frazier Life Sciences Management L.P. (10.42%), Geode Capital Management LLC (0.53%), Octagon Capital Advisors LP (0.41%) and Boothbay Fund Management LLC (0.17%).

How do I buy shares of Maze Therapeutics?

Shares of MAZE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MAZE
• Previous Symbol: NASDAQ:MAZE
• CIK: 1842295
• Web: N/A
• Phone: (650) 850-5070
• Fax: N/A
• Employees: 121
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Maze Therapeutics: $30.17
• High Price Target: $50.00
• Low Price Target: $17.00
• Potential Upside/Downside: +29.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.63
• Quick Ratio: 13.63

Sales & Book Value

• Annual Sales: $2.50 million
• Price / Sales: 408.69
• Cash Flow: $0.14 per share
• Price / Cash Flow: 161.99
• Book Value: ($7.11) per share
• Price / Book: -3.28

Miscellaneous

• Outstanding Shares: 43,851,000
• Free Float: N/A
• Market Cap: $1.02 billion
• Optionable: N/A
• Beta: N/A